WO2018009998A1 - Antimicrobial mucosal formulation and use of the antimicrobial mucosal formulation - Google Patents
Antimicrobial mucosal formulation and use of the antimicrobial mucosal formulation Download PDFInfo
- Publication number
- WO2018009998A1 WO2018009998A1 PCT/BR2017/050189 BR2017050189W WO2018009998A1 WO 2018009998 A1 WO2018009998 A1 WO 2018009998A1 BR 2017050189 W BR2017050189 W BR 2017050189W WO 2018009998 A1 WO2018009998 A1 WO 2018009998A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antimicrobial
- mucosal
- formulation according
- mucosal formulation
- silver
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 37
- 238000009472 formulation Methods 0.000 title claims abstract description 35
- 230000000845 anti-microbial effect Effects 0.000 title claims abstract description 18
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000004332 silver Substances 0.000 claims abstract description 15
- 229910052709 silver Inorganic materials 0.000 claims abstract description 15
- 239000002245 particle Substances 0.000 claims abstract description 8
- 210000004400 mucous membrane Anatomy 0.000 claims abstract description 6
- 239000004599 antimicrobial Substances 0.000 claims abstract description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000000443 aerosol Substances 0.000 claims description 4
- 230000000844 anti-bacterial effect Effects 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- 239000006185 dispersion Substances 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- -1 polyorganosiloxane Polymers 0.000 claims description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 2
- 241000196324 Embryophyta Species 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 229920001615 Tragacanth Polymers 0.000 claims description 2
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims description 2
- 230000003444 anaesthetic effect Effects 0.000 claims description 2
- 230000000202 analgesic effect Effects 0.000 claims description 2
- 230000000843 anti-fungal effect Effects 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 230000000840 anti-viral effect Effects 0.000 claims description 2
- 229940121375 antifungal agent Drugs 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 238000004040 coloring Methods 0.000 claims description 2
- 229960005168 croscarmellose Drugs 0.000 claims description 2
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 239000002324 mouth wash Substances 0.000 claims description 2
- 229940051866 mouthwash Drugs 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000003002 pH adjusting agent Substances 0.000 claims description 2
- 229920001277 pectin Polymers 0.000 claims description 2
- 239000001814 pectin Substances 0.000 claims description 2
- 235000010987 pectin Nutrition 0.000 claims description 2
- 239000004584 polyacrylic acid Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 239000006254 rheological additive Substances 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 238000009736 wetting Methods 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 1
- 239000000305 astragalus gummifer gum Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 3
- 239000011859 microparticle Substances 0.000 abstract description 2
- 239000002105 nanoparticle Substances 0.000 abstract description 2
- 210000004877 mucosa Anatomy 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 229940041678 oral spray Drugs 0.000 description 2
- 239000000668 oral spray Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000003515 anti-microbian Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 229940068984 polyvinyl alcohol Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Definitions
- the present invention relates to a mucosal adherent antimicrobial mucosal formulation comprising silver particles, particularly silver micro or nanoparticles, for the prevention or treatment of mucosal disorders. It further relates to the use of such a formulation.
- Mouth and nose represent the ways in which various conditions, from common flu to H1N1, and even bacterial and fungal infections settle in the human body.
- An emblematic case allowing contamination of the mucous membranes of the nose and mouth is one that occurs where there is crowding of people, particularly indoors. Prevention of infections or contamination of any kind is sought by large numbers of people using cloth masks. Typical examples would be air travel, or hospital areas that visitors have to travel through.
- Such masks generate discomfort in use, as well as disrupt the aesthetics, producing after use a material that requires treatment or burning before disposal.
- Silver is one of the safest antimicrobial agents compared to some organic antimicrobial agents, with important antimicrobial effect and low toxicity to human cells.
- silver particles of the formulation of the invention have typical sizes between 0.5 and 500 nm, particularly between 2 and 100 nm, more particularly between 10 and 50 nm.
- silver is used in the formulation of the invention in the form of colloidal silver.
- nanoprost such particles are termed nanoprost, without imposing any limitations beyond those contained in the appended claims.
- the formulation of the invention during use favors the formation of silver ions.
- the silver content in the formulation of the invention is in the range of 0.1 ppm to 2000 ppm per gram.
- the formulation of the invention is in any form known to the person skilled in the art, suitable for contact with human mucous membranes, for example cream, gel, liquid, ointment, emulsion, dispersion, mouthwash, spray, foam, aerosol.
- the formulation of the invention contains agents of mucosal adhesion, that is, a substrate compatible with mucosal contact, which has some degree of adherence to it, helping to fix the nanoprote in the vicinity of the mucosa.
- Mucosal adhesion agents suitable for the invention may be aqueous or non-aqueous polymeric or non-polymeric substrates, for example chosen from polyethylene glycol, cellulose derivatives (methylcellulose, carboxymethylcellulose, hydroxypropyl methylcellulose, croscarmellose, etc.) polyvinyl pyrrolidone, pectin, hyaluronic acid , chitosan, polyvinyl alcohol, sodium alginate, polyorganosiloxane, polysaccharides, gelatin, gum tragacanth, xanthan gum, caraya gum, polyacrylic acid, soluble starch.
- adhesion agents sometimes called bioadhesive or mucoadhesive, may be of plant or animal origin, or synthetic. May provide immediate, prolonged or delayed release of nanoprost.
- the formulation of the invention may contain excipients adapted for use, for example rheological modifier, pH modifier, wetting, coloring, flavoring, surfactant, diluent, preservative, and any other known to the person skilled in the art.
- the formulation of the invention may contain other topically desired actives such as other antimicrobials (antibacterial, antifungal, antiviral), anti-inflammatory, analgesic, anesthetic, hormone, etc.
- other topically desired actives such as other antimicrobials (antibacterial, antifungal, antiviral), anti-inflammatory, analgesic, anesthetic, hormone, etc.
- Another aspect of the invention is the use of formulation with the characteristics described above to prepare a product useful in preventing or treating mucosal disorders, particularly oral, nasal and vaginal mucosa.
- the formulation of the invention may be indirectly dispensed to the mucosa, which is first applied to a suitable substrate such as cloth or cotton and then applied to the mucosa.
- the following table shows a formulation according to the invention in the form of a topical antibacterial cream.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to an anti-microbial mucosal formulation that adheres to mucous membranes and comprises silver particles, in particular silver microparticles or nanoparticles, and is aimed at the prevention or treatment of diseases affecting the mucous membranes. The invention further relates to the use of this formulation.
Description
FORMULAÇÃO MUCOSAL AN IMICROBIANA E USO DE FORMULAÇÃO MUCOSAL ANTIMICROBIANA ANIMICROBIAN MUCOSAL FORMULATION AND USE OF ANTIMICROBIAN MUCOSAL FORMULATION
A presente invenção refere-se a uma formulação mucosal antimicrobiana aderente a mucosas, compreendendo partículas de prata, particularmente micro ou nanopartícuias de prata, visando prevenção ou tratamento de afecções nas mucosas. Refere-se ainda ao uso de tal formulação. The present invention relates to a mucosal adherent antimicrobial mucosal formulation comprising silver particles, particularly silver micro or nanoparticles, for the prevention or treatment of mucosal disorders. It further relates to the use of such a formulation.
ESTADO DA TÉCNICA TECHNICAL STATE
É sobejamente conhecido que as mucosas do corpo humano são a porta de entrada para muitas doenças. Boca e nariz, por exemplo, representam as vias pelas quais várias afecções, desde gripe comum, até HlNl, e mesmo infecções bacterianas e fúngicas se instalam no corpo humano. It is well known that the mucous membranes of the human body are the gateway to many diseases. Mouth and nose, for example, represent the ways in which various conditions, from common flu to H1N1, and even bacterial and fungal infections settle in the human body.
Já no caso da mucosa vaginal, trata-se de local onde se instalam doenças venéreas, por exemplo. In the case of the vaginal mucosa, this is the place where venereal diseases occur, for example.
Um caso emblemático permitindo contaminação pelas mucosas de nariz e boca é aquele que ocorre onde há aglomeração de pessoas, particularmente em ambientes fechados. A prevenção de infeções ou de algum tipo de contaminação é buscada por grande número de pessoas com a utilização de máscaras de pano. Exemplos típicos seriam viagens de avião, ou áreas hospitalares que visitantes têm que percorrer. An emblematic case allowing contamination of the mucous membranes of the nose and mouth is one that occurs where there is crowding of people, particularly indoors. Prevention of infections or contamination of any kind is sought by large numbers of people using cloth masks. Typical examples would be air travel, or hospital areas that visitors have to travel through.
Tais máscaras geram desconforto no uso, além de atrapalhar a estética, produzindo após seu uso um material que exige tratamento ou queima antes do descarte . Such masks generate discomfort in use, as well as disrupt the aesthetics, producing after use a material that requires treatment or burning before disposal.
DESCRIÇÃO DA INVENÇÃO
Em vista de tais situações, foi desenvolvido uma formulação simples e eficaz, que é uma formulação antimicrobiana mucosal, caracterizada por compreender um agente de adesão à mucosa e partículas de prata. DESCRIPTION OF THE INVENTION In view of such situations, a simple and effective formulation, which is a mucosal antimicrobial formulation, characterized in that it comprises a mucosal adhesion agent and silver particles has been developed.
A prata é um dos mais seguros agentes antimicrobianos , em comparação com alguns agentes orgânicos antimicrobianos, com efeito ant imicrobiano importante e baixa toxicidade para as células humanas . Silver is one of the safest antimicrobial agents compared to some organic antimicrobial agents, with important antimicrobial effect and low toxicity to human cells.
Conforme sentido aqui utilizado, as partículas de prata da formulação da invenção têm tamanhos típicos entre 0,5 e 500 nm, particularmente entre 2 e lOOnm, mais particularmente entre 10 e 50nm. Dentro de uma realização particular, a prata é utilizada na formulação da invenção sob forma de prata coloidal. Apenas por facilidade de exposição, neste texto tais partículas são denominadas nanoprata, sem por isso impor quaisquer limitações além daquelas contidas nas reivindicações anexas. As used herein, silver particles of the formulation of the invention have typical sizes between 0.5 and 500 nm, particularly between 2 and 100 nm, more particularly between 10 and 50 nm. Within a particular embodiment, silver is used in the formulation of the invention in the form of colloidal silver. Just for ease of exposure, in this text such particles are termed nanoprost, without imposing any limitations beyond those contained in the appended claims.
De forma preferencial, sem excluir qualquer outra, a formulação da invenção, durante o uso, favorece a formação de ions de prata. Preferably, without excluding any other, the formulation of the invention during use favors the formation of silver ions.
De forma preferencial, sem excluir qualquer outra, o teor de prata na formulação da invenção encontra-se na faixa de 0,1 ppm a 2000 ppm por grama. Preferably, without excluding any other, the silver content in the formulation of the invention is in the range of 0.1 ppm to 2000 ppm per gram.
A formulação da invenção apresenta-se sob quaisquer formas conhecidas do homem da técnica, adequadas ao contato das mucosas humanas, por exemplo creme, gel, liquido, unguento, emulsão, dispersão, colutório, spray, espuma, aerossol. The formulation of the invention is in any form known to the person skilled in the art, suitable for contact with human mucous membranes, for example cream, gel, liquid, ointment, emulsion, dispersion, mouthwash, spray, foam, aerosol.
A formulação da invenção contém agentes de
adesão à mucosas, ou seja, substrato compatível com o contato à mucosa, que tenha algum grau de aderência à mesma, ajudando a fixar a nanoprata na proximidade da mucosa . The formulation of the invention contains agents of mucosal adhesion, that is, a substrate compatible with mucosal contact, which has some degree of adherence to it, helping to fix the nanoprote in the vicinity of the mucosa.
Agentes de adesão à mucosa adequados à invenção podem ser substratos poliméricos ou não poliméricos, aquosos ou não aquosos, por exemplo escolhidos dentre polietileno glicol, derivados de celulose (metilcelulose, carboximetilcelulose, hidroxipropilmetilcelulose , croscarmelose, etc.) polivinil pirrolidona, pectina, ácido hialurônico, quitosana, álcool polivinílico, alginato de sódio, poliorganosiloxano, polissacarídeos , gelatina, goma tragacanto, goma xantana, goma caraia, ácido poliacrílico, amido solúvel. Tais agentes de adesão, as vezes chamados de bioadesivos ou mucoadesivos , podem ser de origem vegetal ou animal, ou sintéticos. Podem prover liberação da nanoprata de forma imediata, prolongada ou adiada. Mucosal adhesion agents suitable for the invention may be aqueous or non-aqueous polymeric or non-polymeric substrates, for example chosen from polyethylene glycol, cellulose derivatives (methylcellulose, carboxymethylcellulose, hydroxypropyl methylcellulose, croscarmellose, etc.) polyvinyl pyrrolidone, pectin, hyaluronic acid , chitosan, polyvinyl alcohol, sodium alginate, polyorganosiloxane, polysaccharides, gelatin, gum tragacanth, xanthan gum, caraya gum, polyacrylic acid, soluble starch. Such adhesion agents, sometimes called bioadhesive or mucoadhesive, may be of plant or animal origin, or synthetic. May provide immediate, prolonged or delayed release of nanoprost.
A formulação da invenção pode conter excipientes adaptados ao uso, por exemplo modificador reológico, modificador de pH, molhante, corante, flavorizante , surfactante, diluente, conservante, e quaisquer outros conhecidos do homem da técnica. The formulation of the invention may contain excipients adapted for use, for example rheological modifier, pH modifier, wetting, coloring, flavoring, surfactant, diluent, preservative, and any other known to the person skilled in the art.
A formulação da invenção pode conter outros ativos que se deseje dispensar topicamente, como outros antimicrobianos ( antibacteriano, antifúngico, antiviral) , anti-inflamatórios , analgésicos, anestésicos, hormônios, etc. The formulation of the invention may contain other topically desired actives such as other antimicrobials (antibacterial, antifungal, antiviral), anti-inflammatory, analgesic, anesthetic, hormone, etc.
Um outro aspecto da invenção é o uso da
formulação com as características acima descritas para preparar produto útil na prevenção ou tratamento de afecções de mucosas, particularmente mucosas oral, nasal e vaginal. Another aspect of the invention is the use of formulation with the characteristics described above to prepare a product useful in preventing or treating mucosal disorders, particularly oral, nasal and vaginal mucosa.
Se necessário, a formulação da invenção pode ser dispensada à mucosa de forma indireta, qual seja, primeiramente aplicada a um substrato adequado, como pano ou algodão, e em seguida aplicada à mucosa. If necessary, the formulation of the invention may be indirectly dispensed to the mucosa, which is first applied to a suitable substrate such as cloth or cotton and then applied to the mucosa.
São dados a seguir exemplos de realização da invenção, sem impor qualquer limitação ao escopo da mesma além do contido nas reivindicações anexas. The following are examples of embodiments of the invention without imposing any limitation on the scope of the invention beyond that contained in the appended claims.
EXEMPLOS EXAMPLES
EXEMPLO 1 - Creme antibacteriano tópico EXAMPLE 1 - Topical Antibacterial Cream
A tabela a seguir mostra uma formulação conforme a invenção, sob forma de creme antibacteriano tópico The following table shows a formulation according to the invention in the form of a topical antibacterial cream.
* Carbopol 940, produto fornecido pela empresa Lubrizol * Carbopol 940, product supplied by the company Lubrizol
** Natrosol 250 HHR, fornecido pela empresa Ashland *** SilverClean 800, fornecido pela empresa Ética do
Brasil ** Natrosol 250 HHR, provided by Ashland *** SilverClean 800, provided by Brazil
**** Baycusan C1000 , fornecido pela empresa Covestro Modo de preparação **** Baycusan C1000, provided by the company Covestro Preparation
Misturar os ingredientes 1 a 5 até homogeneização. Acertar o pH com trietanolamina a aproximadamente 6,3. Adicionar a prata coloidal (ingrediente 6) com baixa velocidade de dispersão, por exemplo 500 rpm. Mix ingredients 1 to 5 until smooth. Adjust the pH with triethanolamine to approximately 6.3. Add colloidal silver (ingredient 6) with low dispersion speed, eg 500 rpm.
EXEMPLO 2 - Spray Ou Aerossol Oral EXAMPLE 2 - Oral Spray Or Aerosol
A tabela a seguir mostra uma formulação conforme a invenção, sob forma de spray ou aerossol oral . The following table shows a formulation according to the invention in oral spray or aerosol form.
* Carbopol 940, produto fornecido pela empresa Lubrizol * Carbopol 940, product supplied by the company Lubrizol
** Natrosol 250 HHR, fornecido pela empresa Ashland *** SilverClean 800, fornecido pela empresa Ética do Brasil ** Natrosol 250 HHR, supplied by Ashland *** SilverClean 800, provided by Ethics of Brazil
**** Baycusan C1000 , fornecido pela empresa Covestro MODO DE PREPARAÇÃO **** Baycusan C1000, provided by Covestro PREPARATION
Misturar os ingredientes 1 a 5 até
homogeneização. Acertar o pH com trietanolamina a aproximadamente 6,3. Adicionar a prata coloidal (ingrediente 6) com baixa velocidade de dispersão, por exemplo 500 rpm. Mix ingredients 1 through 5 until homogenization. Adjust the pH with triethanolamine to approximately 6.3. Add colloidal silver (ingredient 6) with low dispersion speed, eg 500 rpm.
O técnico no assunto, em vista das informações aqui apresentadas, assim como os exemplos, saberá realizar a invenção de modo distinto do revelado, mas desempenhando a mesma ou substancialmente a mesma função par atingir o mesmo ou substancialmente o mesmo resultado, portanto dentro do escopo da invenção definido nas reivindicações anexas.
The person skilled in the art, in view of the information presented herein, as well as the examples, will know how to carry out the invention differently from that disclosed, but performing the same or substantially the same function to achieve the same or substantially the same result, therefore within the scope. of the invention defined in the appended claims.
Claims
1. Formulação mucosal antimicrobiana caracterizada pelo fato de compreender um agente de adesão à mucosa e partículas de prata. 1. Antimicrobial mucosal formulation characterized by the fact that it comprises a mucosal adhesion agent and silver particles.
2. Formulação mucosal antimicrobiana de acordo com a reivindicação 1 caracterizada pelo fato de que as partículas de prata têm tamanhos entre 0,5 e 500 nm, particularmente 2 e lOOnm, mais particularmente 10 e 50nm. Antimicrobial mucosal formulation according to claim 1, characterized in that the silver particles have sizes between 0.5 and 500 nm, particularly 2 and 100 nm, more particularly 10 and 50 nm.
3. Formulação mucosal antimicrobiana de acordo com a reivindicação 1 caracterizada pelo fato de as partículas de prata estão presentes sob forma de prata coloidal. Antimicrobial mucosal formulation according to Claim 1, characterized in that the silver particles are present in colloidal silver form.
4. Formulação mucosal antimicrobiana de acordo com a reivindicação 1 caracterizada pelo fato de que a formulação contém 0,1 ppm a 2000 ppm de prata por grama. Antimicrobial mucosal formulation according to claim 1, characterized in that the formulation contains 0.1 ppm to 2000 ppm silver per gram.
5. Formulação mucosal antimicrobiana de acordo com a reivindicação 1 caracterizada pelo fato de que o dito agente de adesão à mucosa é escolhido dentre substratos polimérico, não polimérico, aquoso, não aquoso, de origem vegetal, de origem animal ou sintético . Antimicrobial mucosal formulation according to claim 1, characterized in that said mucosal adhesion agent is chosen from polymeric, non-polymeric, aqueous, non-aqueous substrates of plant origin, animal or synthetic origin.
6. Formulação mucosal antimicrobiana de acordo com a reivindicação 1 caracterizada pelo fato de que o dito agente de adesão à mucosa é escolhido dentre polietileno glicol, derivados de celulose (metilcelulose , carboximeti1celulose , hidroxipropilmetilcelulose , croscarmelose, etc.) polivinil pirrolidona, pectina, ácido hialurônico,
quitosana, álcool polivinílico, alginato de sódio, poliorganosiloxano, polissacarideos, gelatina, goma tragacanto, goma xantana, goma caraia, ácido poliacrilico, amido solúvel. Antimicrobial mucosal formulation according to claim 1, characterized in that said mucosal adhesion agent is chosen from polyethylene glycol, cellulose derivatives (methylcellulose, carboxymethylcellulose, hydroxypropyl methylcellulose, croscarmellose, etc.) polyvinyl pyrrolidone, pectin, acid hyaluronic, chitosan, polyvinyl alcohol, sodium alginate, polyorganosiloxane, polysaccharides, gelatin, tragacanth gum, xanthan gum, caraya gum, polyacrylic acid, soluble starch.
7. Formulação mucosal antimicrobiana de acordo com a reivindicação 1 caracterizada pelo fato de que se apresenta sob forma de creme, gel, liquido, unguento, emulsão, dispersão, colutório, spray, espuma ou aerossol. Antimicrobial mucosal formulation according to claim 1, characterized in that it is in the form of a cream, gel, liquid, ointment, emulsion, dispersion, mouthwash, spray, foam or aerosol.
8. Formulação mucosal antimicrobiana de acordo com a reivindicação 1 caracterizada pelo fato de que compreende adicionalmente outros ativos, distintos da prata, escolhidos preferencialmente dentre antibacteriano, antifúngico, antiviral, anti- inflamatório, analgésico, anestésico, hormônio. Antimicrobial mucosal formulation according to claim 1, characterized in that it further comprises other non-silver actives, preferably chosen from antibacterial, antifungal, antiviral, anti-inflammatory, analgesic, anesthetic, hormone.
9. Formulação mucosal antimicrobiana de acordo com a reivindicação 1 caracterizada pelo fato de que compreende ao menos um excipiente. Antimicrobial mucosal formulation according to claim 1, characterized in that it comprises at least one excipient.
10. Formulação mucosal antimicrobiana de acordo com a reivindicação 9 caracterizada pelo fato de que compreende um ou mais excipientes escolhidos dentre modificador reológico, modificador de pH, molhante, corante, flavorizante , surfactante, diluente, conservante. Antimicrobial mucosal formulation according to claim 9, characterized in that it comprises one or more excipients chosen from rheological modifier, pH modifier, wetting, coloring, flavoring, surfactant, diluent, preservative.
11. Uso de formulação mucosal antimicrobiana conforme uma qualquer das reivindicações 1 a 10 caracterizado pelo fato de ser para preparar produto útil na prevenção ou tratamento de afecções de mucosas . Use of an antimicrobial mucosal formulation as claimed in any one of claims 1 to 10 for preparing a product useful in preventing or treating mucosal disorders.
12. Uso de formulação mucosal antimicrobiana
conforme a reivindicação 11 caracterizado pelo fato que as ditas mucosas são oral, nasal ou vaginal.
12. Use of antimicrobial mucosal formulation Claim 11, characterized in that said mucous membranes are oral, nasal or vaginal.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR102016016340-4A BR102016016340A2 (en) | 2016-07-14 | 2016-07-14 | ANTIMICROBIAN MUCOSAL FORMULATION AND USE OF ANTIMICROBIAN MUCOSAL FORMULATION |
| BRBR1020160163404 | 2016-07-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2018009998A1 true WO2018009998A1 (en) | 2018-01-18 |
Family
ID=60952269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/BR2017/050189 WO2018009998A1 (en) | 2016-07-14 | 2017-07-14 | Antimicrobial mucosal formulation and use of the antimicrobial mucosal formulation |
Country Status (2)
| Country | Link |
|---|---|
| BR (1) | BR102016016340A2 (en) |
| WO (1) | WO2018009998A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112759342A (en) * | 2020-12-31 | 2021-05-07 | 厦门高辰新材料有限公司 | Lightweight plastering gypsum and construction method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002085385A2 (en) * | 2001-04-23 | 2002-10-31 | Nucryst Pharmaceuticals Corp. | Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use in the treatment of diseases of the mucosa |
| US20030185889A1 (en) * | 2002-03-27 | 2003-10-02 | Jixiong Yan | Colloidal nanosilver solution and method for making the same |
| US20070081958A1 (en) * | 2003-08-29 | 2007-04-12 | Thorsten Bechert | Body care product containing porous silver particles |
-
2016
- 2016-07-14 BR BR102016016340-4A patent/BR102016016340A2/en not_active Application Discontinuation
-
2017
- 2017-07-14 WO PCT/BR2017/050189 patent/WO2018009998A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002085385A2 (en) * | 2001-04-23 | 2002-10-31 | Nucryst Pharmaceuticals Corp. | Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use in the treatment of diseases of the mucosa |
| US20030185889A1 (en) * | 2002-03-27 | 2003-10-02 | Jixiong Yan | Colloidal nanosilver solution and method for making the same |
| US20070081958A1 (en) * | 2003-08-29 | 2007-04-12 | Thorsten Bechert | Body care product containing porous silver particles |
Non-Patent Citations (2)
| Title |
|---|
| HUMBERTO H LARA ET AL.: "Silver nanoparticles are broad-spectrum bactericidal and virucidal compounds", JOURNAL OF NANOBIOTECHNOLOGY, vol. 9, 2011, pages 30, XP021105520 * |
| JUYOUNG KIM ET AL.: "Antimicrobial effect of silver-impregnated cellulose: potential for antimicrobial therapy", JOURNAL OF BIOLOGICAL ENGINEERING, vol. 3, 2009, pages 20, XP021070021 * |
Also Published As
| Publication number | Publication date |
|---|---|
| BR102016016340A2 (en) | 2018-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6899897B2 (en) | Gum resin as a carrier for topical application of pharmacologically active agents | |
| US8709439B2 (en) | Film-forming resins as a carrier for topical application of pharmacologically active agents | |
| AU777549B2 (en) | Compositions for prevention and treatment of cold and influenza-like symptoms and their methods of use | |
| EP3182957B1 (en) | Cineole-containing composition for nasal application | |
| JP5740393B2 (en) | Composition suitable for topical treatment of fungal infections of the skin and nails | |
| EP1633376B1 (en) | Compositions for prevention and treatment of cold and influenza-like symptoms comprising chelated zinc | |
| EP1711161A2 (en) | Methods of preventing and treating sars using low ph respiratory tract compositions | |
| WO2018009998A1 (en) | Antimicrobial mucosal formulation and use of the antimicrobial mucosal formulation | |
| CN111629711A (en) | Emulsion for topical treatment of skin and mucosal infections | |
| EP1583559A1 (en) | Compositions for prevention and treatment of cold and influenza-like symptoms comprising select mucoadhesive polymers | |
| CA2885218C (en) | Method and composition for treating gastro-esophageal disorders | |
| JP4752987B2 (en) | External preparation composition | |
| US20150250887A1 (en) | Method of preparing resin tinctures | |
| EP2737902A1 (en) | Compositions comprising cimetidine and n,o-carboxymethyl chitosan for the prevention and therapy of pathologies of the skin and the mucous membranes and in the odontostomatological field | |
| US9744125B2 (en) | Use of a virucidal preparation on an area of the face for prevention of transmission or contraction of viral illnesses, or to shorten the duration of, or lessen the severity of viral illnesses | |
| JP2007291073A (en) | Nebulization pharmaceutical formulation for hemorrhoid | |
| US20170326123A1 (en) | Throat solution for treatment of cold, flu and sore throat | |
| EP3273997B1 (en) | Compositions for the treatment of cold | |
| JP2011105764A (en) | External preparation composition | |
| RU2021139253A (en) | PREVENTION OF INFECTION WITH HIGHLY PATHOGENIC VIRUSES BY TOPICAL APPLICATION OF POVIDONE-IODINE TO THE MUCOSA | |
| AU2011244985B2 (en) | Gum resin as a carrier for topical application of pharmacologically active agents | |
| WO2022217319A1 (en) | Composition for prophylaxis against pathogens and methods of use | |
| IT202100022865A1 (en) | COMPOSITIONS WITH ANTIVIRAL ACTION FOR NASAL OR OROPHARYNGEAL ADMINISTRATION BY SPRAY | |
| CN108030782A (en) | The preparation and its application of Azulene sodium sulfonate and Cetylpyridinium Chloride compound gel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17826706 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205 DATED 09-05-2019) |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 17826706 Country of ref document: EP Kind code of ref document: A1 |